A press release reports that the new Trifecta valve with glide technology provides enhanced valve delivery designed to improve implantation during both minimally invasive and conventional valve replacement procedures. It adds that the valve offers enhanced valve delivery to ease implantation in challenging anatomies and surgical approaches.
According to a press release, the first Trifecta GT valve was implanted by Gebrine El Khoury (St-Luc Hospital, Brussels, Belgium). El Khoury has extensive experience with the original Trifecta tissue valve and comments that the new Trifecta GT tissue valve, “will help us provide the best care possible for our patients in need of aortic valve replacement and especially those with challenging clinical cases.”
The original Trifecta valve was designed to provide patients with a tissue valve that was proven to function in the same way as their native aortic valve. Now, the Trifecta GT tissue valve has improved upon the original, and has been designed to provide physicians with a tissue valve option that is easier to implant but that retains its optimal hemodynamic (circulatory) performance.
Alain Leguerrier (Centre Hospitalier Universitaire de Rennes in Rennes, France), says: “The excellent haemodynamic performance of the valve improves quality of life by restoring blood flow both at rest and during exercise, making it an outstanding choice for a wide range of patients. The enhancements to the Trifecta GT tissue valve facilitate improved valve parachuting and seating, which means the valve can gently glide into place.”
Engineered to reduce wear and deterioration over time, the Trifecta GT valve stent is covered with tissue to allow improved tissue-to-tissue contact when the leaflets open and close. Additionally, the valve is treated with St Jude Medical’s Linx AC Treatment—an anticalcification treatment designed to reduce tissue mineralization (hardening). The valve’s fatigue-resistant titanium stent provides a supportive frame within a patient’s heart for added durability.
